Baxiva

Vaccine for urinary tract infections

Over half of all women experience a urinary tract infection (UTI) at least once, with 25% facing recurrent infections. Most UTIs are caused by E. coli, which is becoming increasingly resistant to antibiotics. Pioneer Fellow Giorgia Greter, with Baxiva, is developing a vaccine targeting E. coli’s surface structures. This innovative vaccine reduces the need for antibiotics and improves the quality of life for millions of women.